Intravenous immunoglobulin efficacy on pembrolizumab induced severe toxic epidermal necrolysis

Pembrolizumab is an immune checkpoint inhibitor used in many different cancers. Several immune-related adverse events (irAEs) have been associated with pembrolizumab, including toxic epidermal necrolysis. Here, we are presenting a patient with non-small cell lung cancer that developed toxic epiderma...

Descripción completa

Detalles Bibliográficos
Autores principales: Kian, Waleed, Zemel, Melanie, Elobra, Firas, Sharb, Adam A., Levitas, Dina, Assabag, Yarden, Alguayn, Farouq, Yakobson, Alexander, Rouvinov, Keren, Fuchs, Lior
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8670350/
https://www.ncbi.nlm.nih.gov/pubmed/34321417
http://dx.doi.org/10.1097/CAD.0000000000001162

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8670350/
https://www.ncbi.nlm.nih.gov/pubmed/34321417
http://dx.doi.org/10.1097/CAD.0000000000001162

Ejemplares similares